Hainan Shuangcheng Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jianming Li

İcra Kurulu Başkanı

CN¥828.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.8yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Subdued Growth No Barrier To Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Price

Aug 03

Getting In Cheap On Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) Is Unlikely

Apr 15

CEO

Jianming Li (68 yo)

4.8yrs

Görev süresi

CN¥828,000

Tazminat

Mr. Jianming Li serves as an General Manager of Hainan Shuangcheng Pharmaceutical Co., Ltd. and serves as its Non-Independent director since January 16, 2020. He served as Executive Deputy General Manager...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jianming Li	GM & Non-Independent Director	no data	CN¥828.00k	0.42% CN¥ 42.9m
Xuguang Wang	Financial Director & Chief Financial Officer	14yrs	CN¥380.00k	0.17% CN¥ 17.1m
Xiaofeng Yu	Deputy GM & Secretary of the Board	14yrs	CN¥380.00k	0.16% CN¥ 16.4m
Jianlin Yuan	Deputy General Manager	no data	CN¥494.80k	0.15% CN¥ 15.1m
Zhong Yao	Deputy General Manager	1.8yrs	CN¥833.20k	0.078% CN¥ 7.9m
Shiying Wang	Deputy General Manager	1.8yrs	CN¥367.40k	0.030% CN¥ 3.0m
Yixiang Ai	Deputy General Manager	1.8yrs	CN¥362.80k	0.017% CN¥ 1.8m
Haiyan Li	Deputy General Manager	1.8yrs	CN¥332.60k	0.013% CN¥ 1.3m
Rui Wang	Deputy General Manager	1.8yrs	CN¥332.20k	0.015% CN¥ 1.5m
Yuan Li	Deputy General Manager	1.8yrs	CN¥362.30k	0.016% CN¥ 1.6m
Yun Zhou	Accounting Supervisor	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: 002693 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jianming Li	GM & Non-Independent Director	4.8yrs	CN¥828.00k	0.42% CN¥ 42.9m
Chengdong Wang	Chairman	14yrs	Veri yok	0.51% CN¥ 51.7m
Yingpu Wang	Vice Chairman	14yrs	CN¥796.00k	15.58% CN¥ 1.6b
Bin Fu	Non-Employee Supervisor	14yrs	Veri yok	Veri yok
Jing Bai	Vice Chairman	2.8yrs	Veri yok	Veri yok
Hongyu Wang	Chairman of the Supervisory Board	7.8yrs	Veri yok	Veri yok
Jianwei Li	Independent Director	1.8yrs	CN¥60.00k	Veri yok
Jianhua Xiao	Independent Director	1.8yrs	CN¥60.00k	Veri yok
Ying Chen	Non-Employee Supervisor	1.8yrs	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002693 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Hainan Shuangcheng Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 06, 2022

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Elects Bai Jing as Non-Independent Director

Recent updates

Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.024 loss in 3Q 2023)

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

New major risk - Revenue and earnings growth

Subdued Growth No Barrier To Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Price

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: CN¥0.021 loss per share (vs CN¥0.011 profit in 1Q 2023)

Getting In Cheap On Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) Is Unlikely

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Share price stability

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.006 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.006 loss in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.05 loss in FY 2021)

Less than half of directors are independent

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments

Third quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.024 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.023 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.008 loss in 1Q 2021)

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 06, 2022

Full year 2021 earnings released: CN¥0.05 loss per share (vs CN¥0.13 loss in FY 2020)

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Elects Bai Jing as Non-Independent Director

Third quarter 2021 earnings released: CN¥0.94 loss per share (vs CN¥0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.011 (vs CN¥0.036 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.13 loss per share (vs CN¥0.06 profit in FY 2019)

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 21, 2021

New 90-day low: CN¥3.69

New 90-day low: CN¥3.91

New 90-day low: CN¥4.45

Third quarter earnings released

New 90-day low: CN¥4.84

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥5.00

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş